The effect of bronchodilators in the exercise capacity and thoracoabdominal mechanics of subjects with bronchiectasis: a randomized crossover, double-blinded, placebo-controlled trial
C. Marques Da Silva (SP, Brazil), D. Silva Queiroz (SP, Brazil), R. Athanazio (SP, Brazil), S. Dal Corso (SP, Brazil), S. Rached (SP, Brazil), A. Lunardi (SP, Brazil), R. Vitorasso (SP, Brazil), H. Moriya (SP, Brazil), A. Fonseca (SP, Brazil), C. Carvalho (SP , Brazil)
Source: Virtual Congress 2020 – Exercise tolerance and functional status across respiratory diseases
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Marques Da Silva (SP, Brazil), D. Silva Queiroz (SP, Brazil), R. Athanazio (SP, Brazil), S. Dal Corso (SP, Brazil), S. Rached (SP, Brazil), A. Lunardi (SP, Brazil), R. Vitorasso (SP, Brazil), H. Moriya (SP, Brazil), A. Fonseca (SP, Brazil), C. Carvalho (SP , Brazil). The effect of bronchodilators in the exercise capacity and thoracoabdominal mechanics of subjects with bronchiectasis: a randomized crossover, double-blinded, placebo-controlled trial. 286
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Short-term effect of a single dose of inhaled procaterol on exercise performance in COPD: a randomized, double blind, placebo-controlled, crossover trial Source: Annual Congress 2008 - Physiological response to exercise performance Year: 2008
A randomised double-blind placebo-controlled trial of the effect of inhaled heparin on lung function, hyperinflation and exercise capacity in patients with COPD Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016
A randomised, placebo-controlled trial of inhaled mannitol in patients with bronchiectasis Source: Annual Congress 2008 - Infectious lung diseases including tuberculosis Year: 2008
Tiotropium treatment for bronchiectasis (ROBUST): a randomized, placebo-controlled, crossover trial Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017
Working memory training efficacy in COPD: the randomised, double-blind, placebo-controlled Cogtrain trial Source: ERJ Open Res, 7 (4) 00475-2021; 10.1183/23120541.00475-2021 Year: 2021
Acute effects of nasal high-flow during exercise in COPD patients after an exacerbation : a randomized controlled cross-over trial Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies Year: 2019
Long-term benefits of airway clearance in bronchiectasis: a randomised placebo-controlled trial Source: Eur Respir J, 51 (1) 1701926; 10.1183/13993003.01926-2017 Year: 2018
A randomized, double-blind, placebo-controlled study to evaluate the role of formoterol in management of acute asthma Source: Eur Respir J 2006; 28: Suppl. 50, 498s Year: 2006
A randomized double-blind placebo-controlled trial on the short and long-term effects of electro acupuncture on moderate to severe asthma Source: Eur Respir J 2006; 28: Suppl. 50, 502s Year: 2006
Pulmonary vasodilator therapy in severe COPD: a double-blind, placebo-controlled trial Source: Eur Respir J 2007; 30: Suppl. 51, 525s Year: 2007
A double-blind randomised controlled trial of protein supplementation to enhance exercise capacity in COPD during pulmonary rehabilitation: a pilot study Source: ERJ Open Res, 7 (1) 00077-2021; 10.1183/23120541.00077-2021 Year: 2021
Randomised, double-blind, placebo-controlled trial of EPS® 7630 in adults with COPD Source: Annual Congress 2009 - Healthcare and treatment of COPD Year: 2009
RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations Source: Virtual Congress 2021 – ALERT: COPD Year: 2021
Efficacy and safety of revefenacin (REV), a long-acting muscarinic antagonist for nebulization: results of replicate randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe COPD Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017
Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial. Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018
Omalizumab efficacy following cat allergen exposure: Results from a randomized, double-blind, placebo-controlled, parallel-group study in patients with moderate asthma Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010
A double-blind double dummy randomised placebo-controlled cross-over design clinical trial of formoterol delivered by two different dry powder devices in prevention of bronchoconstriction induced by methacholine in mild to moderate persistent asthma in adult patients Source: Annual Congress 2009 - Airway hyperresponsiveness: mechanism and assessment Year: 2009
A single-centre, placebo-controlled, double-blinded, randomized, cross-over study of Iloprost in patients with Eisenmenger syndrome Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018
Randomized double-blind placebo-controlled trial of azithromycin in lung transplantation: first results Source: Annual Congress 2008 - New insights and treatment options for bronchiolitis obliterans syndrome after lung transplantation Year: 2008
Quality of life in patients with COPD and nocturnal supplemental oxygen-therapy: a prospective, placebo-controlled cross-over trial Source: Eur Respir J 2005; 26: Suppl. 49, 289s Year: 2005